Sandbox/00008

Cardiogenic Shock Resident Survival Guide
Overview
Causes
FIRE
Diagnosis
Treatment
Do's
Don'ts

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, MBChB. [2]

FIRE: Focused Initial Rapid Evaluation

A Focused Initial Rapid Evaluation (FIRE) should be performed to identify patients in need of immediate intervention.

Boxes in the red signify that an urgent management is needed.

Abbreviations: CBC, complete blood count; CI, cardiac index; CK-MB, creatine kinase MB isoform; CVP, central venous pressure; DC, differential count; ICU, intensive care unit; INR, international normalized ratio; LFT, liver function test; MAP, mean arterial pressure; PCWP, pulmonary capillary wedge pressure; PT, prothrombin time; PTT, partial prothrombin time; SaO2, arterial oxygen saturation; SBP, systolic blood pressure; ScvO2, central venous oxygen saturation; SvO2, mixed venous oxygen saturation; SMA-7, sequential multiple analysis-7.

Does the patient have cardinal findings that increase the pretest probability of cardiogenic shock? ❑  Evidence of end-organ hypoperfusion ❑  Altered mental status ❑  Cold extremities ❑  Cyanosis ❑  Oliguria (urine output <0.5 mL/kg/h) ❑  Sustained hypotension ❑  SBP <90 mm Hg for ≥30 min or ❑  MAP ↓ >30 mm Hg below baseline for ≥30 min ❑  Presence of myocardial dysfunction after exclusion or correction of non-myocardial factors contributing to tissue hypoperfusion

YES

NO

Cardiogenic shock suspected

Proceed to shock resident survival guide

Immediate management ❑  ECG monitor ❑  Pulse oximeter ❑  Arterial blood gas ❑  Intubation with mechanical ventilation ❑  Large-bore peripheral venous lines ❑  Arterial line ❑  Central venous catheter ❑  Pulmonary artery catheter ❑  Foley catheter ❑  ICU admission ❑  Cardiology consultation ❑  Hold antihypertensive medications

Immediate workup ❑  CBC/DC/SMA-7/LFT/PT/PTT/INR ❑  Cardiac troponins, CK-MB ❑  BNP, NT-proBNP ❑  Lactate ❑  12-Lead ECG ❑  Chest radiograph ❑  Echocardiography

Cardiogenic shock confirmed (click for details on criteria)

Optimization of hemodynamic parameters

Preload (click for details) ❑  Goal: PCWP 15–18 mm Hg, CVP 8–12 cm H2O ❑  Fluid challenge protocol ("TROL") ❑  ± Correct pulmonary congestion ❑  ± Furosemide 40 mg slow IV injection ❑  ± Morphine 2–4 mg slow IV injection

Afterload (click for details) ❑  Goal: MAP >65 mm Hg, SVR 800–1200 dyn·s·cm−5 ❑  If ↑ MAP & ↑ SVR: wean vasopressors ± vasodilators ❑  If ↓ MAP & ↑ SVR: vasopressors + inotropes ❑  If ↓ MAP & ↓ SVR: vasopressors ± vasopressin

Cardiac index (click for details) ❑  Goal: CI >2.2 L/min/m2 ❑  ± Dobutamine ❑  ± Milrinone

Optimization of perfusion and oxygenation

❑  Endpoints: ❑  SaO2 >92% ❑  SvO2 >60% ❑  ScvO2 >70% ❑  Urine output >0.5 mL/kg/h ❑  Lactate <2.2 mM/L ❑  Hematocrit ≥30% ❑  Consider IABP, VAD, or ECMO ❑  ± Correct tachyarrhythmias and bradyarrhythmias ❑  ± Correct acid-base and electrolyte disturbance

Acute myocardial infarction likely? ❑  Positive cTnT, cTnI, or CK-MB AND ❑  Symptoms of myocaridal ischemia OR ❑  New significant ST–T changes or LBBB

YES, then proceed to acute ischemia pathway

No, then proceed to complete diagnostic approach

Do's

Criteria for Cardiogenic Shock [Return to FIRE]

• Clinical Criteria

• Sustained hypotension (SBP <90 mm Hg or MAP 30 mm Hg below baseline in preexisting hypertension for at least 30 minutes)
• Evidence of tissue hypoperfusion (such as oliguria, cyanosis, cool extremities, and altered mental status)
• Presence of myocardial dysfunction after exclusion or correction of non-myocardial factors contributing to tissue hypoperfusion (such as hypovolemia, hypoxia, and acidosis)

• Hemodynamic Criteria

• Sustained hypotension (SBP <90 mm Hg or MAP 30 mm Hg below baseline in preexisting hypertension for at least 30 minutes)
• Depressed cardiac index (<1.8 L/min/m² of BSA without support or <2.0–2.2 L/min/m² of BSA with support) in the presence of an elevated wedge pressure (>15 mm Hg).

Hemodynamic Optimization [Return to FIRE]

Preload [Return to FIRE]

• Preload optimization involves manipulation of PCWP and/or CVP levels and correction of pulmonary congestion.

Fluid Challenge Protocol

• Protocolized fluid administration titrated to hemodynamic and clinical endpoints secures the efficacy of tissue perfusion and oxygenation.

• Four elements of the fluid challenge protocol: type of fluid (T), rate of fluid administration (R), objective (O), and limits (L).

• 1. Type of fluid (T)

• The choice of crystalloid or colloid solution should be made on the basis of the underlying disease, the nature of fluid deficit, the severity of circulatory failure, the serum albumin concentration, and the risk of bleeding.
• There were no significant differences in mortality between saline and albumin infusion for critically ill patients.
• Blood transfusion may be considered in the presence of profound anemia or massive hemorrhage.
• Hyperchloremic acidosis may be associated with the use of isotonic saline solution.

• 2. Rate of fluid administration (R)

• Based on the level of pulmonary capillary wedge pressure or central venous pressure, a volume of 50, 100, or 200 ml of fluid is administered over a 10-minute interval through a peripheral venous catheter.

Baseline PCWP (mm Hg) Baseline CVP (cm H2O) Rate of fluid administration ≥16 ≥14 50 mL over 10 minutes <16 but ≥12 <14 but ≥8 100 mL over 10 minutes <12 <8 200 mL over 10 minutes

• 3. Objective (O)

• Fluid administration should be titrated to reach predetermined clinical endpoints such as resolution of tachycardia or oliguria, improved skin perfusion or level of consciousness, normalization of lactate concentrations, and restoration of adequate blood pressure or ventricular filling pressure.

• 4. Limits (L)

• Fluid administration should be stopped if the safety limits are violated to minimize the risk of developing pulmonary edema.
• Inotropes, vasodilators, or mechanical circulatory device may be required if signs of hypoperfusion persist despite optimal fluid loading.
• Hemodynamic safety limits based on PCWP (the 7–3 rule) or CVP (the 5–2 rule):

↑ PCWP (mm Hg) ↑ CVP (cm H2O) Action ≥7 ≥5 Stop fluid administration <7 but >3 <5 but >2 Wait and recheck pressure after 10 minutes ≤3 ≤2 Continue fluid administration

Pulmonary Congestion

• Findings suggestive of cardiogenic pulmonary edema:

• History and clinical manifestations

• Cough
• Dyspnea
• Expectoration of frothy sputum
• Orthopnea
• Paroxysmal nocturnal dyspnea
• Signs and symptoms of heart failure
• Signs and symptoms of hypoxemia
• Signs and symptoms of myocardial ischemia
• Signs and symptoms of valvular dysfunction
• Tachypnea

• Physical examination

• Cool extremities
• Heart murmurs
• Hepatomegaly
• Inspiratory crackles or rhonchi
• Jugular venous distention
• S3 gallop
• Peripheral edema

• Laboratory and hemodynamic findings

• BNP > 500 pg/mL
• PCWP >18 mm Hg

• Radiologic findings

• Central infiltrates with peripheral sparing
• Cephalization of pulmonary vessels
• Enlarged cardiac silhouette
• Enlargement of peribronchovascular spaces
• Increased opacity of acinar areas that coalesce into frank consolidations
• Kerley B lines
• Peribronchial cuffing
• Pleural effusions
• Vascular pedicle width >70 mm

• Radiologic manifestations of pulmonary congestion reflect the extent of elevation in wedge pressure:

PCWP (mm Hg) Phase of Pulmonary Congestion Findings on Chest Radiograph 18–20 Onset of pulmonary congestion Redistribution of pulmonary flow to the upper lobes ("cephalization") and Kerley lines 20–25 Moderate congestion Diminished clarity of the borders of medium-sized pulmonary vessels ("perihilar haze") 25–30 Severe congestion Radiolucent grapelike clusters surrounded by radiodense fluid ("periacinar rosette") >30 Onset of pulmonary edema Coalescence of periacinar rosettes resulting in "Bat's wing" opacities

• Furosemide

• Dosage and Administration

• For acute pulmonary edema, the initial dose is 40 mg injected slowly intravenously (over 1 to 2 minutes).
• If a satisfactory response does not occur within 1 hour, the dose may be increased to 80 mg injected slowly intravenously (over 1 to 2 minutes).

• Contraindications

• Anuria
• Hypersensitivity to furosemide

• Morphine

• Dosage and Administration

• Morphine may be used adjunctively in the treatment of acute pulmonary edema at a dose of 2–4 mg (slow IV injection over 1–5 minutes) every 5–30 minutes as needed.

• Contraindications

• Hypersensitivity to morphine sulfate is one of the contraindications to its use.
• Morphine should not be used in convulsive states, such as those occurring in status epilepticus, tetanus, and strychnine poisoning.
• Morphine is also contraindicated in the following conditions: respiratory insufficiency or depression; bronchial asthma; heart failure secondary to chronic lung disease; cardiac arrhythmias; increased intracranial or cerebrospinal pressure; head injuries; brain tumor; acute alcoholism; and delirium tremens.

Afterload [Return to FIRE]

Cardiac Index [Return to FIRE]

Criteria for Acute Myocardial Infarction [Return to FIRE]

• Detection of a rise and/or fall of cardiac biomarker values (preferably cardiac troponin) with at least one value above the 99th percentile upper reference limit and with at least one of the following:

• Symptoms of ischemia

• Recent episode of typical ischemic discomfort that either is of new onset or is severe or that exhibits an accelerating pattern of previous stable angina (especially if it has occurred at rest or is within 2 weeks of a previously documented MI)
• Chest pain or severe epigastric pain, nontraumatic in origin, with components typical of myocardial ischemia or MI:

• Central/substernal compression or crushing chest pain
• Pressure, tightness, heaviness, cramping, burning, aching sensation
• Unexplained indigestion, belching, epigastric pain
• Radiating pain in neck, jaw, shoulders, back, or 1 or both arms

• New or presumably new significant ST-segment–T wave (ST–T) changes or new left bundle branch block (LBBB).
• Development of pathological Q waves in the ECG.
• Imaging evidence of new loss of viable myocardium or new region wall motion abnormality.
• Identification of an intracoronary thrombus by angiography or autopsy.

References